.jpg)
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
The FDA has accepted Novo Nordisk's application for a label expansion for oral GLP-1 treatment Rybelsus to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
The FDA has accepted Novo Nordisk's application for a label expansion for oral GLP-1 treatment Rybelsus to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
